Reach Us +44-1904-929220
Utilization And Cost Of Prostate-specifi C Antigen (PSA) As A Biomarker Among Prostate Cancer Patients: Results From Taiwan National Health Insurance Research Database | 3691

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Utilization and cost of prostate-specifi c antigen (PSA) as a biomarker among prostate cancer patients: Results from Taiwan national health insurance research database

2nd World Congress on Biomarkers & Clinical Research

Yi-Hsien Lin

ScientificTracks Abstracts: J Mol Biomark Diagn

DOI: 10.4172/2155-9929.S1.2

I n medical and pharmaceutical research, interest in using biomarkers as surrogate endpoints for target clinical endpoint has stemmed from various reasons. Because of importance of statistical evaluation of surrogate marker, very diff erent methods are suggested. Alonso et al. proposed the ?likelihood reduction factor? (LRF) as a unifi ed approach when neither the biomarker nor the true endpoint is normally distributed. Th is measure of individual- level association can be used under any genera lized linear model for a single trial or meta- analysis. Flowing of these criteria for surrogate evaluation, in this study, we have explored the Bayesian approach to the evaluation of the validity of a surrogate at the individual level, based on the Bayes factor for choosing the best model in the context of generalized linear modeling. It is suggested that the Bayesian LRF denoted by LRFB which benefi ts from the prior knowledge on the situation under study would perform yet better in comparison to other criteria. By a Th eorem we proof, for large sample size, Lim LRF B =LRF. Th e relation between the Bayesian likelihood reduction factor (LRF B ) and its frequentist counterpart (LRF) have been shown by a small scale simulation also. We have simulated diff erent trials with diff erent priors in the logistic regression models by R soft ware. Th e results show that LRF can be viewed as a special case of LRFB relative to a certain prior. Hence, the importance of prior knowledge and Bayesian analysis for surrogate?s validation is shown
Shohreh Jalaie has completed her Ph.D in Biostatistics from Tarbiat Modares University in 2008. She passed a scholarship in Melbourne University. She is faculty member of Tehran University of Medical Science. She has published more than 20 papers in reputed journals.
Relevant Topics